caa a22 4500 469079592 CHVBK 20180323132946.0 cr unu---uuuuu 170328e19920501xx s 000 0 eng 10.1007/BF00168955 doi (NATIONALLICENCE)springer-10.1007/BF00168955 Pharmacokinetic interaction between carbamazepine and neuroleptics after combined prolonged treatment in rats [Elektronische Daten] [W. Daniel, L. Janczar, L. Danek, W. Legrum, K.J. Netter] Summary: This study investigates how neuroleptics of phenothiazine or thioxanthene structure influence the pharmacokinetics of carbamazepine. Experiments were carried out on male Wistar rats. Carbamazepine and the neuroleptics were administered i.p., separately or together, for 2 weeks in the following daily doses (mg/kg): carbamazepine 15 during the 1st week of treatment and 20 during the 2nd week of treatment, promazine 10, chlorpromazine 2, perazine 10, chlorprothixene 2, flupenthixol 0.5. One hour after the last injection of carbamazepine and/or the neuroleptic, samples of blood plasma and brain were taken to determine the concentrations of carbamazepine and two of its metabolites: 10,11-epoxide and trans- 10,11-diol. The neuroleptics increased the concentration of carbamazepine in plasma and in brain, but tended to decrease (with the exception of chlorpromazine) the concentration of the epoxide and increased the concentration of trans-10,11-diol. Metabolic in vitro studies did not show any significant differences between rats treated with carbamazepine alone and those treated with carbamazepine plus neuroleptic in the rates of the carbamazepine epoxidation, of 10,11-epoxide hydrolysis or of 1-naphthol glucuronidation. Springer-Verlag, 1992 Carbamazepine nationallicence Drug combination nationallicence Neuroleptics nationallicence Carbamazepine plasma levels nationallicence Inhibitory interaction nationallicence Daniel W. Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland aut Janczar L. Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland aut Danek L. Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland aut Legrum W. Department of Pharmacology and Toxicology, University of Marburg, Lahnberge, Marburg, Federal Republic of Germany aut Netter K.J. Department of Pharmacology and Toxicology, University of Marburg, Lahnberge, Marburg, Federal Republic of Germany aut Naunyn-Schmiedeberg's Archives of Pharmacology Springer-Verlag 345/5(1992-05-01), 598-605 0028-1298 345:5<598 1992 345 210 https://doi.org/10.1007/BF00168955 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00168955 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Daniel W. Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland aut NATIONALLICENCE 700 1- Janczar L. Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland aut NATIONALLICENCE 700 1- Danek L. Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland aut NATIONALLICENCE 700 1- Legrum W. Department of Pharmacology and Toxicology, University of Marburg, Lahnberge, Marburg, Federal Republic of Germany aut NATIONALLICENCE 700 1- Netter K.J. Department of Pharmacology and Toxicology, University of Marburg, Lahnberge, Marburg, Federal Republic of Germany aut NATIONALLICENCE 773 0- Naunyn-Schmiedeberg's Archives of Pharmacology Springer-Verlag 345/5(1992-05-01), 598-605 0028-1298 345:5<598 1992 345 210 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer